Search research articles
Contact Us
Filters
Showing results (41-50 of 91) with videos related to
Page
of 10
Sort By:
Aktuelle Urologie
|
October 2, 2004
[Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens]
L Prikler, E Scandella, Y Men, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 16, 2023
Next generation radiotheranostics promoting precision medicine
K L Pomykala, B A Hadaschik, O Sartor, et al.
Prostate Cancer and Prostatic Diseases
|
September 15, 2005
Hypertriglyceridemia as a possible risk factor for prostate cancer
L Wuermli, M Joerger, S Henz, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 14, 1998
Analysis of the multiple interactions between IL-12 and the high affinity IL-12 receptor complex
D H Presky, L J Minetti, S Gillessen, et al.
Prostate Cancer and Prostatic Diseases
|
March 11, 2015
Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09)
M Joerger, R H N van Schaik, M L Becker, et al.
Blood
|
February 27, 2001
Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3
M H Tomasson, I R Williams, S Li, et al.
ESMO Open
|
August 1, 2024
Penile cancer: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up
A Muneer, M Bandini, E Compérat, et al.
Cancer Chemotherapy and Pharmacology
|
October 30, 2013
Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction
M Joerger, A D R Huitema, D Koeberle, et al.
British Journal of Cancer
|
November 28, 2007
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV
S Steinbild, K Mross, A Frost, et al.
European Journal of Immunology
|
January 1, 1995
Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist
S Gillessen, D Carvajal, P Ling, et al.
Page
of 10
Search research articles
Search
Showing results (41-50 of 91) with videos related to
Sort By:
Page
of 10
Aktuelle Urologie
|
October 2, 2004
[Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens]
L Prikler, E Scandella, Y Men, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 16, 2023
Next generation radiotheranostics promoting precision medicine
K L Pomykala, B A Hadaschik, O Sartor, et al.
Prostate Cancer and Prostatic Diseases
|
September 15, 2005
Hypertriglyceridemia as a possible risk factor for prostate cancer
L Wuermli, M Joerger, S Henz, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 14, 1998
Analysis of the multiple interactions between IL-12 and the high affinity IL-12 receptor complex
D H Presky, L J Minetti, S Gillessen, et al.
Prostate Cancer and Prostatic Diseases
|
March 11, 2015
Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09)
M Joerger, R H N van Schaik, M L Becker, et al.
Blood
|
February 27, 2001
Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3
M H Tomasson, I R Williams, S Li, et al.
ESMO Open
|
August 1, 2024
Penile cancer: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up
A Muneer, M Bandini, E Compérat, et al.
Cancer Chemotherapy and Pharmacology
|
October 30, 2013
Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction
M Joerger, A D R Huitema, D Koeberle, et al.
British Journal of Cancer
|
November 28, 2007
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV
S Steinbild, K Mross, A Frost, et al.
European Journal of Immunology
|
January 1, 1995
Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist
S Gillessen, D Carvajal, P Ling, et al.
Page
of 10